Plimoth Trust Co. LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,531 shares of the biopharmaceutical company’s stock after buying an additional 675 shares during the period. Gilead Sciences comprises about 1.0% of Plimoth Trust Co. LLC’s holdings, making the stock its 26th biggest position. Plimoth Trust Co. LLC’s holdings in Gilead Sciences were worth $2,786,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Gradient Investments LLC raised its stake in shares of Gilead Sciences by 16.1% during the fourth quarter. Gradient Investments LLC now owns 1,076 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 149 shares in the last quarter. Waldron Private Wealth LLC raised its stake in shares of Gilead Sciences by 3.8% during the third quarter. Waldron Private Wealth LLC now owns 4,372 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 162 shares in the last quarter. Cornerstone Advisors Inc. raised its stake in shares of Gilead Sciences by 6.1% during the third quarter. Cornerstone Advisors Inc. now owns 3,120 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 178 shares in the last quarter. Boenning & Scattergood Inc. raised its stake in shares of Gilead Sciences by 0.9% during the fourth quarter. Boenning & Scattergood Inc. now owns 20,176 shares of the biopharmaceutical company’s stock worth $1,262,000 after acquiring an additional 180 shares in the last quarter. Finally, NewSquare Capital LLC raised its stake in shares of Gilead Sciences by 0.9% during the fourth quarter. NewSquare Capital LLC now owns 20,165 shares of the biopharmaceutical company’s stock worth $1,261,000 after acquiring an additional 187 shares in the last quarter. Institutional investors and hedge funds own 80.03% of the company’s stock.
Gilead Sciences stock opened at $65.94 on Thursday. The company has a market capitalization of $87.28 billion, a P/E ratio of 10.72, a PEG ratio of 66.65 and a beta of 1.19. Gilead Sciences, Inc. has a 12-month low of $60.32 and a 12-month high of $82.71. The company has a quick ratio of 3.29, a current ratio of 3.36 and a debt-to-equity ratio of 1.09.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the previous year, the company earned $1.78 earnings per share. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. Analysts forecast that Gilead Sciences, Inc. will post 6.23 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be paid a $0.63 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $2.52 dividend on an annualized basis and a yield of 3.82%. Gilead Sciences’s dividend payout ratio (DPR) is presently 37.07%.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $71.20, for a total value of $3,560,000.00. Following the sale, the director now owns 2,877,762 shares in the company, valued at $204,896,654.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.16% of the company’s stock.
Several analysts recently weighed in on the stock. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Thursday, November 8th. Raymond James reiterated a “buy” rating on shares of Gilead Sciences in a report on Thursday, November 1st. Mizuho set a $94.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, November 1st. Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a report on Wednesday, October 31st. Finally, Guggenheim initiated coverage on shares of Gilead Sciences in a research note on Monday, December 17th. They issued a “buy” rating and a $86.00 price target on the stock. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $84.01.
ILLEGAL ACTIVITY WARNING: This piece was reported by Highlight Press and is owned by of Highlight Press. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://highlightpress.com/2019/02/14/gilead-sciences-inc-gild-stake-lifted-by-plimoth-trust-co-llc.html.
Gilead Sciences Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Recommended Story: Understanding Analyst Ratings
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.